Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadunolimab in Combination With Azacitidine and Venetoclax in MDS and AML
NCT06548230Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nadunolimab in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2025; status: recruiting.
02
Drugs
nadunolimab
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06548230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548230.